On August 29, 2023, Novartis released new long-term data from its ORION-8 Phase 3 clinical trial. The data showed that its twice-yearly RNAi therapy, Leqvio (Inclisiran, Sodium Echociliran), in combination with statins.

On August 29, 2023, AbbVie submitted a new indication application to the US FDA and European EMA for Skyrizi (Risankizumab) for the treatment of moderate to severe ulcerative colitis (UC) in adults.

Merck announced that Merck announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1 (Combined Positive Score≥1).

The Center for Drug Evaluation, NMPA (CDE) shows that the application for the listing of Overland Pharmaceutical's CD19 antibody-drug conjugate (ADC), Loncastuximab, has been accepted. This is also the first China-reported ADC targeting CD19. CD19 is a popular target in the development of antitumor drugs. If Loncastuximab is approved, multiple types of drugs, including monoclonal antibodies, bispecific antibodies, CAR-T cells, and ADCs, will fulfill this target. We take Loncastuximab as an example to retrieve its related biological sequences.

AEON Biopharma, Inc. has shared encouraging results from their recent Phase 2 medical trial of ABP-450.

TScan Therapeutics, Inc.announced today that the U.S. FDA has given approval for its new experimental drug TSC-203-A0201, a TCR-T pinpointing PReferentially expressed Antigen in Melanoma.

SparingVision has shared encouraging early safety data from the Phase I/II clinical trial of its primary gene-agnostic gene therapy, SPVN06, designed to treat retinitis pigmentosa.

This article summarized the latest R&D progress of Methimazole, the Mechanism of Action for Methimazole, and the drug target R&D Trends for Methimazole.

Janssen has filed an additional Biologics License Application with the U.S. Food and Drug Administration, seeking endorsement for RYBREVANT® (amivantamab-vmjw) to be combined with Chemotherapy.

This article summarized the latest R&D progress of Sevelamer Carbonate, the Mechanism of Action for Sevelamer Carbonate, and the drug target R&D trends for Sevelamer Carbonate.

Tourmaline Bio reported that the FDA has conditionally approved the Investigational New Drug (IND) application for TOUR006.

Research on tumor immune evasion and tolerance mediated by exosomes has found that tumor cells can produce a large amount of exosomes.